EHA 2022 | Two-year follow-up data of a Phase I study investigating zamtocabtagene autoleucel in R/R NHL
In this video, Peter Borchmann, MD, University Hospital Cologne, Cologne, Germany, discusses the two-year follow-up data of a Phase I study investigating the use of zamtocabtagene autoleucel (MB-CART2019.1) for the treatment of patients with relapsed/refractory (R/R) B-cell non-Hodgkin lymphoma (NHL) (NCT03870945). This study showed that dual CD20/CD19 targeting provided major advantages in terms of efficacy and tolerability, seeing a complete remission (CR) in 5 out of 12 patients as well as no dose-limiting toxicities (DLTs). Prof. Borchmann also talks on the ongoing DALY 2-EU trial (NCT04844866), which is seeking to determine superiority of this agent compared to standard of care (SoC) therapy in patients with R/R diffuse large B-cell lymphoma (DLBCL) ineligible for high-dose chemotherapy. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
